SillaJen, Inc. (215600.KQ)
KRW 2565.0
(0.79%)
KRW 2565.0
(0.79%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.45 Billion KRW | 12.83% |
| 2022 | -18.76 Billion KRW | -8.54% |
| 2021 | -17.28 Billion KRW | 2.48% |
| 2020 | -17.72 Billion KRW | 66.1% |
| 2019 | -52.3 Billion KRW | 0.16% |
| 2018 | -52.38 Billion KRW | -15.87% |
| 2017 | -45.21 Billion KRW | -6.46% |
| 2016 | -42.47 Billion KRW | -102.99% |
| 2015 | -20.92 Billion KRW | -1103.08% |
| 2014 | 2.08 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -4.31 Billion KRW | 6.78% |
| 2024 Q2 | -4.72 Billion KRW | 90.85% |
| 2023 Q3 | -3.9 Billion KRW | -12.38% |
| 2023 FY | -16.35 Billion KRW | 12.83% |
| 2023 Q4 | -4.62 Billion KRW | -18.69% |
| 2023 Q1 | -3.02 Billion KRW | 51.94% |
| 2023 Q2 | -3.47 Billion KRW | -14.67% |
| 2022 Q2 | -3.4 Billion KRW | 28.77% |
| 2022 FY | -18.76 Billion KRW | -8.54% |
| 2022 Q1 | -4.77 Billion KRW | 16.84% |
| 2022 Q4 | -6.29 Billion KRW | -74.58% |
| 2022 Q3 | -3.6 Billion KRW | -6.03% |
| 2021 Q2 | -3.55 Billion KRW | 6.28% |
| 2021 Q4 | -5.74 Billion KRW | -36.84% |
| 2021 FY | -17.28 Billion KRW | 2.48% |
| 2021 Q1 | -3.79 Billion KRW | -575.5% |
| 2021 Q3 | -4.19 Billion KRW | -18.02% |
| 2020 FY | -17.72 Billion KRW | 66.1% |
| 2020 Q4 | 797.93 Million KRW | 457.34% |
| 2020 Q3 | 143.16 Million KRW | -72.8% |
| 2020 Q2 | 526.43 Million KRW | 160.38% |
| 2020 Q1 | 202.17 Million KRW | -76.76% |
| 2019 Q3 | 691.86 Million KRW | -88.35% |
| 2019 Q1 | 1.56 Billion KRW | 36.0% |
| 2019 FY | -52.3 Billion KRW | 0.16% |
| 2019 Q4 | 870.11 Million KRW | 25.76% |
| 2019 Q2 | 5.93 Billion KRW | 278.8% |
| 2018 Q2 | 2.06 Billion KRW | -5.35% |
| 2018 Q4 | 1.15 Billion KRW | -49.94% |
| 2018 Q3 | 2.3 Billion KRW | 11.25% |
| 2018 FY | -52.38 Billion KRW | -15.87% |
| 2018 Q1 | 2.18 Billion KRW | -1.13% |
| 2017 Q2 | 1.84 Billion KRW | 5.99% |
| 2017 FY | -45.21 Billion KRW | -6.46% |
| 2017 Q1 | 1.73 Billion KRW | 67.58% |
| 2017 Q4 | 2.21 Billion KRW | 105.8% |
| 2017 Q3 | 1.07 Billion KRW | -41.63% |
| 2016 Q4 | 1.03 Billion KRW | -36.07% |
| 2016 Q2 | 1.17 Billion KRW | -19.81% |
| 2016 Q1 | 1.46 Billion KRW | -5.69% |
| 2016 FY | -42.47 Billion KRW | -102.99% |
| 2016 Q3 | 1.62 Billion KRW | 38.31% |
| 2015 Q3 | -119.66 Million KRW | -151.26% |
| 2015 Q4 | 1.55 Billion KRW | 1395.47% |
| 2015 Q2 | 233.46 Million KRW | 60.11% |
| 2015 Q1 | 145.81 Million KRW | -82.63% |
| 2015 FY | -20.92 Billion KRW | -1103.08% |
| 2014 FY | 2.08 Billion KRW | 0.0% |
| 2014 Q2 | 639.36 Million KRW | 204.85% |
| 2014 Q3 | 397.3 Million KRW | -37.86% |
| 2014 Q4 | 839.46 Million KRW | 111.29% |
| 2014 Q1 | 209.73 Million KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 124.229% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | 68.06% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 97.429% |
| Bioneer Corporation | 199.25 Billion KRW | 99.269% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | 34.186% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | 96.375% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | 0.018% |
| Helixmith Co., Ltd | 2.12 Billion KRW | 31.346% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 99.429% |
| Medy-Tox Inc. | 128.16 Billion KRW | 98.863% |
| Peptron, Inc. | 1.14 Billion KRW | -27.72% |
| Amicogen, Inc. | 51.51 Billion KRW | 97.172% |
| Genexine, Inc. | 387.48 Million KRW | -275.948% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | 78.239% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | 91.815% |
| ALTEOGEN Inc. | 31.19 Billion KRW | 95.331% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 99.201% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | 94.52% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | 89.899% |
| Genomictree Inc. | -1.03 Billion KRW | 240.261% |
| MedPacto, Inc. | -1.83 Billion KRW | 179.488% |
| D&D Pharmatech | 18.67 Billion KRW | 92.2% |
| EASY BIO,Inc. | 50.88 Billion KRW | 97.137% |
| GI Innovation, Inc. | 1.98 Billion KRW | 26.776% |